Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection

11/18/2021 | 08:30am EST

Exact Sciences Corp. announced an agreement with Jefferson Health (Jefferson) to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test. This unique effort will engage primary care and specialty providers, care coordinators, and patients from diverse populations across the Jefferson enterprise in research that aims to evaluate MCED test safety and efficacy and help determine how to facilitate the implementation of effective MCED testing in the future. Jefferson is conducting developmental research on patient and provider engagement and plans to participate in Exact Sciences' FDA registration study for its MCED test. Exact Sciences and Jefferson also plan to publish results of their work in this important area.


ę S&P Capital IQ 2021
All news about EXACT SCIENCES CORPORATION
01/10Exact Sciences' Q4 Revenue Outlook Beats Estimates But Caution Warranted on Screening B..
MT
01/10EXACT SCIENCES : Announces Preliminary Fourth Quarter 2021 Results - Form 8-K
PU
01/10Exact Sciences Provides Q4, Full-Year 2021 Revenue Guidance
MT
01/10Exact Sciences Acquires PreventionGenetics for $190 Million in Cash, Stock
MT
01/10Exact Sciences Corporation Reports Preliminary Unaudited Revenue Guidance for the Fourt..
CI
01/10Exact Sciences Corp. and OncXerna Therapeutics, Inc. Announce Licensing Agreement to He..
CI
01/09Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy ..
PR
01/09Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Can..
PR
01/09Exact Sciences Corporation acquired PreventionGenetics LLC for $190 million.
CI
01/03EXACT SCIENCES : Madison School Nurses Tour COVID-19 Lab
PU
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 751 M - -
Net income 2021 -515 M - -
Net Debt 2021 1 330 M - -
P/E ratio 2021 -26,0x
Yield 2021 -
Capitalization 13 515 M 13 515 M -
EV / Sales 2021 8,48x
EV / Sales 2022 7,56x
Nbr of Employees 4 900
Free-Float -
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | EXAS | US30063P1057 | MarketScreener
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 78,43 $
Average target price 126,71 $
Spread / Average Target 61,6%
EPS Revisions
Managers and Directors
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors